|
Q-1479
|
Wednesday, September 23, 2026 |
With regard to the government's responses to questions Q-1386 and Q-1387 on the Order Paper, the Minister of Health's statements that Canada Health Infoway was "not completely fulfilling its mission" and that "the situation with the CEO of that company is unacceptable," the withholding of $50 million in federal funding, and the multiphase review and audit of Canada Health Infoway announced in June 2026: (a) what are the complete terms of reference of the review and audit, including the specific questions being examined about (i) whether Canada Health Infoway fulfilled its mission, (ii) the former President and Chief Executive Officer, (iii) governance, (iv) executive compensation and performance pay, (v) PrescribeIT, (vi) the use of federal funds; (b) what are the details of each phase, including (i) which entity is conducting each phase, (ii) the date on which each phase began, (iii) the current status of each phase; (c) what is the expected completion date of each phase and of the review and audit as a whole; (d) will the government publicly release the full terms of reference, interim findings, final report and all supporting assessments, and, if so, on what dates, and if not, what is the rationale for withholding each document; (e) will the public release include the government's determination of which parts of Canada Health Infoway's mission were not completely fulfilled and what "situation with the CEO" the minister considered unacceptable; (f) have any interim findings already been provided to the Minister of Health, the Deputy Minister of Health, or Health Canada's representative on the Canada Health Infoway board and, if so, on what dates and will those findings be tabled; (g) what public reporting, summary, or other disclosure is planned for Parliament, including the Standing Committee on Health; and (h) is the release of the withheld $50 million conditional on the completion or public disclosure of the review and audit, and what other conditions remain outstanding? |
Awaiting response |
Monday, November 16, 2026 |
|
Q-1389
|
Wednesday, June 17, 2026 |
With regard to Health Canada’s Senior Assistant Deputy Minister in their capacity as the federal government's appointee to the Board of Directors of Canada Health Infoway since 2022: (a) for each Board vote since 2022, regarding the approval of performance pay for the President and Chief Executive Officer, was the federal government’s appointee present, broken down by date of vote; (b) for each instance in (a) where the federal government’s appointee was present, did they vote to (i) approve, (ii) oppose, (iii) abstain from, the approval of performance pay; (c) for each board vote since 2022 concerning the approval of performance pay for senior executives other than the President and Chief Executive Officer, was the federal government’s appointee present, broken down by date of vote and executive position; (d) for each instance in (c) where the federal government’s appointee was present, did they vote to (i) approve, (ii) oppose, (iii) abstain from, the approval of performance pay; (e) prior to each vote in (a) and (c), did the federal government’s appointee advise the Minister of Health how they intended to vote; and (f) for each instance in (e) where the federal government’s appointee advised the Minister of Health, what was the date of the communication? |
Answered |
Monday, September 21, 2026 |
|
Q-1387
|
Wednesday, June 17, 2026 |
With regard to the Minister of Health’s statement during Question Period on May 7, 2026 on Canada Health Infoway, where she stated “I agree that the situation with the CEO of that company is unacceptable”: what “situation with the CEO” was she specifically referring to that she termed “unacceptable”? |
Answered |
Monday, September 21, 2026 |
|
Q-1386
|
Wednesday, June 17, 2026 |
With regard to the Minister of Health’s statement during Question Period on June 8, 2026, that “we realized that Canada Health Infoway was not completely fulfilling its mission”: which parts of Canada Health Infoway’s mission was she referring to as not being completely fulfilled? |
Answered |
Monday, September 21, 2026 |
|
Q-1146
|
Tuesday, April 28, 2026 |
With regard to the government’s response to the Canadian Academy of Health Sciences assessment on fetal alcohol spectrum disorder: (a) has the government developed an implementation plan in response to the report's findings and recommendations, and, if so, what is the plan; (b) which of the report’s findings and recommendations is the government planning to implement, and what is the current status and timeline for the implementation of each recommendation; and (c) for each recommendation, which department or agency is responsible for leading its implementation? |
Answered |
Monday, June 15, 2026 |
|
Q-1057
|
Tuesday, April 14, 2026 |
With regard to the “Subsection 56(1) class exemption in relation to urgent public health need sites in the provinces and territories”, since 2023 and broken down by calendar year: how many urgent public health need sites were operational at any point during the calendar year in each province and territory? |
Answered |
Monday, June 1, 2026 |
|
Q-973
|
Thursday, March 19, 2026 |
With regard to government contracts with advertising agencies, since January 2020, broken down by department or agency and by year: what are the details of each contract, including (i) the name of the advertising agency, (ii) the contract value, (iii) the start and end dates of the contract, (iv) the description of the advertising campaign or the purpose for which the agency was paid, (v) the media or platforms on which the advertising was placed, (vi) whether the contract was awarded through a competitive or non-competitive process, (vii) the description of the services provided? |
Answered |
Wednesday, May 6, 2026 |
|
Q-955
|
Thursday, March 12, 2026 |
With regard to all federal funding provided to MySafe Society since January 2020: (a) what are the details of each contribution, grant and contract, including the (i) department or agency providing the funding, (ii) total value, (iii) start and end dates, (iv) purpose of the funding; (b) for each expenditure in (a), did the agreement require MySafe Society to report to the government on (i) participant health outcomes, (ii) overdose events, (iii) diversion of dispensed substances to unregistered individuals; (c) what reporting, if any, was received by the government under the requirements in (b); (d) was any audit or evaluation of the agreements in (a) conducted, and, if so, what were the findings; (e) what are the details of any federal funding specifically used for the acquisition, installation or operation of drug-dispensing machines, including the (i) number of machines funded, (ii) locations where machines were installed, (iii) total federal contribution toward the machines; and (f) at the time each funding agreement was signed, was the federal government aware that MySafe Society would be using federal funds to dispense opioids through machines, and, if so, (i) which department or official approved the funding with that knowledge, (ii) what controlled substances were known to be dispensed, (iii) what safeguards, if any, were required as a condition of funding? |
Answered |
Wednesday, May 6, 2026 |
